Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The FOMO Trade

<< Previous

Bullboard Posts

Next >>

Comment by mrv2000on Mar 16, 2021 10:23am

186 Views

Post# 32806899

RE:The FOMO Trade

maybe it is.. tho company is far far further along than it was last year when it hit the 8's.. and got smashed down. like 70 million and good stage 2's

new fancy pants DR. with a track record of making big deals... if the drugs work..

ill play the nuance bet.. 20 mill upfront for 10 % of market = is more than 20 million

fully funded stage 3?

ok some monkey games in the near term.

GLA

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market